Stockreport

Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings

Pharvaris N.V. - Ordinary Shares  (PHVS) 
PDF ZUG, Switzerland, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor anta [Read more]